Company: ABBV
Filing Date: 2025-01-06
Form Type: 8-K
Source: 0001551152-25-000002
Chunk: 0

Company: AbbVie Inc.
Filing Date: 2025-01-06
Form: 8-K
Item: Item 2.02
Chunk 0
---
Item 2.02 Results of Operations and Financial Condition

Reported GAAP earnings and adjusted non-GAAP earnings for the fourth quarter of 2024 are expected to include acquired IPR& D and milestones expense of $1.6 billion on a pre-tax basis, representing an unfavorable impact of $0.88 to both GAAP diluted earnings per share and adjusted non-GAAP diluted earnings per share. Results for the quarter ended December 31, 2024 have not been finalized and are subject to our financial statement closing procedures. There can be no assurance that our final results will not differ from these preliminary estimates.

While acquired IPR& D and milestones expense may be incurred upon execution of collaborations, licensing agreements, and other asset acquisitions, AbbVie does not forecast acquired IPR& D and milestones expense due to uncertainty of the future occurrence and timing of these transactions. Adjusted diluted earnings per share guidance for 2024 previously announced on October 30, 2024 excluded the impact of acquired IPR& D and milestones expense that may be incurred beyond the third quarter of 2024. AbbVie’s full-year 2024 adjusted diluted earnings per share guidance range, including the impact of fourth quarter 2024 acquired IPR& D and milestones expense, is $10.02 - $10.06. AbbVie’s fourth quarter 2024 adjusted diluted earnings per share guidance range, including the impact of fourth quarter 2024 acquired IPR& D and milestones expense, is $2.06 - $2.10.

Furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference is guidance for 2024 including the estimated acquired IPR& D and milestones expense incurred during the fourth quarter of 2024.

The information set forth in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed "Filed" for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities thereof, nor shall it be incorporated by reference into future filings by AbbVie Inc. under the Exchange Act or under the Securities Act of 1933, as amended, except to the extent specifically provided in any such filing.

Forward-Looking Statements

Some statements in this Current Report on Form 8-K are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The